Opioid Prescribing Guidelines From US FDA Could Be A While After NASEM Report
Executive Summary
National Academies report identifies gaps in the existing data – including on the question of whether developing prescribing guidelines would even have an impact on the opioid epidemic.
You may also be interested in...
Opioid Approval Standards Could Change Under New US FDA Plan
The Overdose Prevention Framework includes considering whether FDA should require new opioids show superior safety compared to existing products.
Califf Says Opioid Labeling Changes, Withdrawals Still Possible
The US FDA commissioner also suggests the pain medications along with marijuana products should be regulated differently than other drugs.
Non-Opioid Pain Treatments Likely Not Eligible For Accelerated Approval, US FDA Says
Other expedited pathways like fast track, priority review or breakthrough could be appropriate, according to new draft guidance.